Aklief costs roughly $760 to $890 for a single 45-gram pump without insurance, making it one of the most expensive topical acne treatments on the market. For comparison, generic tretinoin cream costs about $33 for a 20-gram tube. That enormous price gap comes down to a few reinforcing factors: Aklief is a patented, first-in-class medication with no generic competition, and it won’t have any for years.
A New Type of Retinoid With No Generic Version
Aklief’s active ingredient, trifarotene, is a fourth-generation retinoid and the first to selectively target a specific receptor in the skin called RAR-gamma. Older retinoids like tretinoin and adapalene activate multiple receptors, which is partly why they cause more widespread irritation. Trifarotene is 16 times more selective for RAR-gamma than for the next closest receptor and 65 times more selective than for the least relevant one. Because RAR-gamma is the most abundant retinoid receptor in skin cells, this precision lets the drug work on the intended target while producing fewer off-target effects.
Developing a molecule with that kind of selectivity required years of research and clinical testing. Galderma, the company behind Aklief, holds patents on trifarotene that don’t expire until May 2033. Until then, no other manufacturer can sell a generic version. Two companies have filed applications with the FDA to eventually produce generics, but those won’t reach pharmacies until the patent window closes or a legal challenge succeeds. That decade-plus of market exclusivity is the single biggest reason the price stays high: Galderma faces zero price competition from equivalent products.
How Aklief Compares to Cheaper Retinoids
The cost difference between Aklief and generic retinoids is staggering. A 45-gram pump of Aklief runs about $760 without discounts. A 20-gram tube of generic tretinoin costs around $33. Even accounting for the size difference, Aklief costs more than ten times as much per gram. Adapalene (the ingredient in Differin) is available over the counter for under $15 at most drugstores.
From a clinical standpoint, all three are retinoids that unclog pores and reduce inflammation. The case for Aklief rests on its receptor selectivity and its FDA approval for treating acne on the trunk (back, shoulders, chest), not just the face. If you’re managing facial acne alone and tolerating a generic retinoid well, the price premium may not translate into a meaningfully better outcome for you. But for people who haven’t responded to older retinoids or who need treatment across larger body areas, Aklief fills a gap that generics don’t.
Insurance Barriers Add to the Frustration
Even with insurance, getting Aklief covered often involves extra steps. Major insurers like UnitedHealthcare require prior authorization before they’ll pay for it. Their criteria are straightforward but strict: you need an acne diagnosis, and you must have already tried and failed (or be unable to use) either over-the-counter Differin gel or generic tretinoin cream. Only after documenting that those cheaper options didn’t work will coverage kick in.
If your prior authorization is approved, commercial insurance can bring your copay down dramatically, sometimes to as little as $20 per pump. But if your insurer denies the request, or if you’re on a plan that excludes Aklief from its formulary entirely, you’re looking at the full retail price. This step-therapy requirement exists precisely because Aklief is expensive, and insurers want to confirm that a lower-cost retinoid genuinely isn’t an option before covering it.
Ways to Lower the Cost
Galderma offers a savings program called the CareConnect card. If you have commercial insurance, the card can reduce your copay to as low as $20 per 45-gram pump at participating pharmacies. If you’re uninsured or paying entirely out of pocket, the same card brings the price down to $90 per pump, which is a significant drop from the roughly $890 retail price.
Pharmacy discount tools like GoodRx can also help. Current GoodRx pricing brings the cost of a 45-gram pump to around $693, a meaningful discount but still a large out-of-pocket expense compared to generics. It’s worth checking both the manufacturer card and discount platforms, since the better deal depends on your insurance status and which pharmacy you use.
The Bigger Picture on Brand-Name Pricing
Aklief’s price follows the same pattern seen across dermatology and other specialties: a novel compound with genuine clinical advantages launches at a premium, protected by patents that prevent competition for a decade or more. The manufacturer sets a high list price knowing that most patients will pay far less through insurance or savings programs, while the retail price captures maximum revenue from the fraction of prescriptions filled at full cost.
This dynamic shifts only when patents expire and generics enter the market. With two generic applications already on file at the FDA and the last qualifying patent expiring in 2033, competition is coming, but it’s still years away. Until then, Aklief’s price reflects the combination of a first-in-class molecule, a single manufacturer, and an insurance system that uses the drug’s cost as leverage to steer patients toward cheaper alternatives first.